Affinity Grow

Affinity Grow’s mix in August 2026 concentrated 49.5% of sales in Flower while placing rank 6 in Connecticut Flower, yet Flower fell 29.9% month over month and 29.9% year over year, dragging overall sales down 19.3% YoY. Vapor Pens held 27.5% share but declined 10.7% MoM and 26.9% YoY, whereas Pre-Roll at 13.5% share slipped 29.6% MoM but inched up 3.3% YoY. The outlier was Concentrates at 6.9% share, up 315.5% MoM and 2,757.4% YoY, alongside modest average price inflation of 3.0% YoY to $30.71. The pattern implies a pivot away from shrinking core inhalables toward a fast-scaling Concentrates line that is not yet large enough to offset Flower and Vapor Pens contractions, keeping category reliance concentrated despite share churn.

Given Flower’s 49.5% share and 29.9% MoM drop versus Concentrates’ 6.9% share and 315.5% MoM surge, the brand’s risk profile is tied to a weakening primary category while growth is accruing in a smaller niche. With Vapor Pens down 26.9% YoY and Pre-Roll up 3.3% YoY but down 29.6% MoM, the short-term trajectory points to volatility across inhalables rather than stable substitution. Holding rank 6 in Connecticut Flower while average prices rose 3.0% YoY suggests pricing is not the main lever; instead, mix realignment is the lever, and the implication is that scaling Concentrates and stabilizing Pre-Roll penetration are the most direct paths to buffer core-category drawdown and reduce dependence on a single rank-constrained segment.